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Primary health care should play bigger role in
treating chronic kidney disease
A new review article suggests that primary health care should play a
bigger role in managing early-stage chronic kidney disease. Olivier J.
Wouters and Dr. Panos G. Kanavos, two of the co-authors of the study,
discuss these findings.
Chronic kidney disease (CKD), which involves the gradual loss of kidney
function, is one of the most common health conditions in the world and a
major cause of kidney failure. CKD affects more than 10 per cent of the
adult population in many high-income countries, and it is estimated that
more than $1 trillion is spent worldwide on kidney failure treatment.
Although CKD is a leading public health concern, there is disagreement
about what constitutes appropriate care. Various clinical guidelines and
health organizations—like the National Institute for Health and Care
Excellence in the UK and the American College of Physicians in the USA—
offer differing recommendations about the screening, diagnosis and
treatment of CKD, especially for the early stages of the disease.
With colleagues from Salford Royal NHS Foundation Trust and the US
National Institutes of Health (NIH), we conducted a literature review to
analyse which interventions are most effective for early-stage CKD. We
also explored what the optimum time is to provide clinical care for
patients with early-stage CKD and what model of care is most suitable for
these patients. Our findings were published in Nature Reviews
Nephrology.
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We found that primary care interventions should play a more prominent
role in the treatment and management of patients in the early stages of
CKD than it currently does. The evidence suggests that:
Type 2 diabetes and high blood pressure are usually the underlying
causes of CKD; CKD can worsen if these related diseases are left
uncontrolled;
CKD care should focus more on preventing the deterioration of
health in those with related conditions than on costly specialist
care;
Preventive measures – for example, healthy eating habits, regular
exercise, smoking cessation and cholesterol and blood pressure
control – can improve cardiovascular and kidney health outcomes;
There are substantial shortcomings in the way CKD patients are
currently being treated and managed in primary care, notably
suboptimal prescribing and management for those patients who
also have hypertension and Type 2 diabetes;
More research is needed to better understand the risk factors for
CKD progression; this would allow clinicians to focus their attention
on the patients who are most likely to develop kidney failure.
However, the available evidence for CKD is of variable quality. In
comparison to other common diseases, such as Type 2 diabetes and
stroke, there is a lack of evidence on the clinical and economic benefits of
different care strategies for early-stage CKD.
Researchers and policymakers should examine how to improve health-
care delivery to high-risk populations. Importantly, more evidence is
needed on how to better coordinate care between primary-care
physicians and nephrologists and other kidney disease specialists.
Researchers should evaluate different models of CKD care in terms of
value for money, and economic analyses should ideally be conducted
alongside health-outcome evaluations.
The development of CKD registries would further our knowledge about
the effectiveness of various treatment strategies. Registries – databases
which contain information on the health status, health-care use, and
health-care costs of patients with a particular condition – should be set
up to facilitate economic analyses. Such analyses can guide future models
of care.
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